Kiora Pharmaceuticals Has Been Granted European Patent Number EP3139914 Titled "Compounds For Treating Ophthalmic Diseases And Disorders"
Portfolio Pulse from Happy Mohamed
Kiora Pharmaceuticals has been granted European Patent Number EP3139914 for compounds treating ophthalmic diseases and disorders. This patent could potentially strengthen Kiora's product pipeline and market position.
June 26, 2023 | 4:49 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Kiora Pharmaceuticals' newly granted European Patent EP3139914 could strengthen its product pipeline and market position in the ophthalmic sector.
The granted patent directly pertains to Kiora Pharmaceuticals' core business of developing treatments for ophthalmic diseases and disorders. This patent could potentially lead to new products and strengthen Kiora's market position, positively impacting its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100